Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics

References

• WHO. WHO Coronavirus (COVID-19) Dashboard. [Internet]. cited 2021 Dec 19]. Available from: https://covid19.who.int.
   Google Scholar
• Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126–2128.
   PubMed Web of Science ®Google Scholar
• Jackson CB, Farzan M, Chen B, et al. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20.
   PubMed Web of Science ®Google Scholar
• Battaglini D, Robba C, Ball L, et al. Emerging therapies for COVID-19 pneumonia. Expert Opin Investig Drugs. 2020;29(7):633–637.
   PubMed Web of Science ®Google Scholar
• Babaei F, Mirzababaei M, Nassiri‐Asl M, et al. Review of registered clinical trials for the treatment of COVID‐19. Drug Dev Res. 2021;82(4):474–493.
   PubMed Web of Science ®Google Scholar
• WHO. WHO Therapeutics and COVID-19: living guideline. 2021 Dec 7.
   Google Scholar
• NIH. Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. NIH COVID-19 treat. Guidel. 2021 cited 2022 Jan 5]. Available from: https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/.
   Google Scholar
• IDSA. IDSA guidelines on the treatment and management of patients with COVID-19 [Internet]. 29 June 2022. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#.
   Google Scholar
• Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021;57(4):2100048.
   PubMed Web of Science ®Google Scholar
• Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607.
   PubMed Web of Science ®Google Scholar
• Lopes-Pacheco M, Silva PL, Cruz FF, et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. Front Physiol. 2021;12:593223.
   PubMed Web of Science ®Google Scholar
• Robba C, Battaglini D, Pelosi P, et al. Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2. Expert Rev Respir Med. 2020;14(9):865–868.
   PubMed Web of Science ®Google Scholar
• Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032.
   PubMed Web of Science ®Google Scholar
• Meduri GU, Carratu P, Freire AX. Evidence of biological efficacy for prolonged glucocorticoid treatment in patients with unresolving ARDS. Eur Respir J. 2003;22(Supplement 42):57s–64s.
   PubMedGoogle Scholar
• Ma S, Xu C, Liu S, et al. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. Signal Transduct Target Ther. 2021;6(1):83.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Murthy S, Diaz JV, et al., Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19. JAMA. 2020;324(13): 1330.
   PubMed Web of Science ®Google Scholar
• Tang H-J, Lai -C-C. The association between corticosteroid uses and mortality among severe COVID-19 patients. J Infect. 2021;82(2):e24.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020;384:693–704.
   PubMed Web of Science ®Google Scholar
• Dequin P-F, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically Ill patients with COVID-19. JAMA. 2020;324(13):1298.
   PubMed Web of Science ®Google Scholar
• Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. JAMA. 2020;324(13):1317.
   PubMed Web of Science ®Google Scholar
• Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. JAMA. 2020;324(13):1307.
   PubMed Web of Science ®Google Scholar
• Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. rationale and design. Ann Am Thorac Soc. 2020;17(7):879–891.
   PubMed Web of Science ®Google Scholar
• Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021;72(9):e373–e381.
   PubMed Web of Science ®Google Scholar
• Munch MW, Meyhoff TS, Helleberg M, et al. Low‐dose hydrocortisone in patients with COVID‐19 and severe hypoxia: the COVID STEROID randomised, placebo‐controlled trial. Acta Anaesthesiol Scand. 2021;65(10):1421–1430.
   PubMed Web of Science ®Google Scholar
• Russell L, Uhre KR, Lindgaard ALS, et al. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia. JAMA. 2021;326(18):1807.
   PubMed Web of Science ®Google Scholar
• Granholm A, Munch MW, Myatra SN, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Med. 2022;48(1):45–55.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772.
   PubMed Web of Science ®Google Scholar
• L-M Y, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843–855.
   PubMed Web of Science ®Google Scholar
• Agustí A, De Stefano G, Levi A, et al. Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. Eur Respir J. 2022;59(3):2103036.
   PubMed Web of Science ®Google Scholar
• Rochwerg B, Agarwal A, Zeng L, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ. 2020;370:m2924.
   PubMedGoogle Scholar
• Yan D, Ra OH, Yan B. The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. Anim Dis. 2021;1(1):15
   PubMedGoogle Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, et al. Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19. Ann Intern Med. 2021;174(9):1261–1269.
   PubMed Web of Science ®Google Scholar
• Lingas G, Néant N, Gaymard A, et al. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. J Antimicrob Chemother. 2022;77(5):1404–1412.
   PubMed Web of Science ®Google Scholar
• WHO Solidarity Trial Consortium. repurposed antiviral drugs for Covid-19 — interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399(10339):1941–1953.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19. Final Report. N Engl J Med. 2020;383(19):1813–1826.
   Google Scholar
• Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021;S1473-3099: 00485–0.
   Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA. 2020;324(11):1048.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827–1837.
   PubMed Web of Science ®Google Scholar
• Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. Can Med Assoc J. 2022;194(7):E242–E251.
   PubMed Web of Science ®Google Scholar
• Hoek JM, Field SM, de Vries YA, et al. Retinking remdesivir for COVID-19: a bayesian reanalysis of trial findings. PLoS One. 2021;16(7):e0255093.
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386(4):305–315.
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950.
   PubMed Web of Science ®Google Scholar
• Sung Y-K, Lee YH. Comparison of the efficacy and safety of tocilizumab, sarilumab, and sirukumab in comparison with Adalimumab as monotherapy in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021;59(9):618–626.
   PubMed Web of Science ®Google Scholar
• RECOVERY collaborative group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397:1637–1645.
   PubMed Web of Science ®Google Scholar
• Albuquerque A, Tramujas L, Sewanan L, et al. Tocilizumab in COVID-19 – a Bayesian reanalysis of RECOVERY [Internet]. medRxiv. 2021 cited 2022 Mar 21]. Available from 2022 Mar 21: https://www.medrxiv.org/content/10.1101/2021.06.15.21258966v1.
   Google Scholar
• Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):511–521.
   PubMed Web of Science ®Google Scholar
• REMAP-CAP investigators. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–1502.
   PubMed Web of Science ®Google Scholar
• Hermine O, Mariette X, Tharaux P-L, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. JAMA Intern Med. 2021;181(1):32.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503–1516.
   PubMed Web of Science ®Google Scholar
• Salama C, Han J, Yau L, et al. tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30.
   PubMed Web of Science ®Google Scholar
• Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383(24):2333–2344.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Diaz G, Gottlieb RL, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021;47(11):1258–1270.
   PubMed Web of Science ®Google Scholar
• Broman N, Feuth T, Vuorinen T, et al. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM—a prospective, randomized, single-centre, open-label study. Clin Microbiol Infect. 2022;28(6):844–851.
   PubMed Web of Science ®Google Scholar
• Lescure F-X, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):522–532.
   PubMed Web of Science ®Google Scholar
• Merchante N, Cárcel S, Garrido-Gracia JC, et al. Early Use of sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial. Antimicrob Agents Chemother. 2022;66(2):e02107–21.
   Web of Science ®Google Scholar
• Branch-Elliman W, Ferguson R, Doros G, et al. De Socio GV. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: a pragmatic, embedded randomized clinical trial. PLoS One. 2022;17(2): e0263591.
   PubMed Web of Science ®Google Scholar
• Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407–1418.
   PubMed Web of Science ®Google Scholar
• Lamontagne F, Agoritsas T, Siemieniuk R, et al. A living WHO guideline on drugs to prevent covid-19. BMJ. 2021;372:526.
   Google Scholar
• Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021;373:949.
   Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar
• Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406–415.
   PubMed Web of Science ®Google Scholar
• Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752–1760.
   PubMed Web of Science ®Google Scholar
• Kyriazopoulou E, Huet T, Cavalli G, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3(10):e690–e697.
   PubMedGoogle Scholar
• Tharaux P-L, Pialoux G, Pavot A, et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;9(3):295–304.
   PubMed Web of Science ®Google Scholar
• Caricchio R, Abbate A, Gordeev I, et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19. JAMA. 2021;326(3):230.
   PubMed Web of Science ®Google Scholar
• Ghati N, Bhatnagar S, Mahendran M, et al. Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial). BMC Infect Dis. 2022;22(1):606.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet.2022;399:143–151.
   PubMed Web of Science ®Google Scholar
• REMAP-CAP Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, Lawler PR, et al. Effect of antiplatelet therapy on survival and organ support-free days in critically Ill patients with COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1247–1259.
   PubMed Web of Science ®Google Scholar
• Remap-cap T. ACTIV-4a and AI. therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med. 2021;385:777–789.
   PubMed Web of Science ®Google Scholar
• Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021;7(1):e001455.
   PubMed Web of Science ®Google Scholar
• Mehta KG, Patel T, Chavda PD, et al. Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials. RMD Open. 2021;7(3):e001746.
   PubMed Web of Science ®Google Scholar
• Diaz R, Orlandini A, Castellana N, et al. Effect of colchicine vs usual care alone on intubation and 28-day mortality in patients hospitalized with COVID-19. JAMA Network Open. 2021;4(12):e2141328.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir Med. 2021;9(12):1419–1426.
   PubMed Web of Science ®Google Scholar
• Cecconi A, Martinez-Vives P, Vera A, et al. Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial. Sci Rep. 2022;12(1):9208.
   PubMed Web of Science ®Google Scholar
• Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019. JAMA Network Open. 2020;3(6):e2013136.
   PubMed Web of Science ®Google Scholar
• Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Heal. 2022;10(1):e42–e51.
   PubMed Web of Science ®Google Scholar
• Franchini M, Glingani C, Liumbruno GM. Potential mechanisms of action of convalescent plasma in COVID-19. Diagnosis. 2021;8(4):413–420.
   Web of Science ®Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA. 2020;324(5):460.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397:10289:2049–2059.
   PubMed Web of Science ®Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–629.
   PubMed Web of Science ®Google Scholar
• Körper S, Weiss M, Zickler D, et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest. 2021;131(20):e152264.
   PubMed Web of Science ®Google Scholar
• Sekine L, Arns B, Fabro BR, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J. 2022;59(2):2101471.
   PubMed Web of Science ®Google Scholar
• Menichetti F, Popoli P, Puopolo M, et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia. JAMA Network Open. 2021;4(11):e2136246.
   PubMed Web of Science ®Google Scholar
• Ortigoza MB, Yoon H, Goldfeld KS, et al. Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients. JAMA Intern Med. 2022;182(2):115.
   PubMed Web of Science ®Google Scholar
• van den Berg K, Glatt TN, Vermeulen M, et al. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Sci Rep. 2022;12(1):2552.
   PubMedGoogle Scholar
• Devos T, Van Thillo Q, Compernolle V, et al. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: dawn-plasma. Eur Respir J. 2022;59(2):2101724.
   PubMed Web of Science ®Google Scholar
• Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–618.
   PubMed Web of Science ®Google Scholar
• Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E, et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;131(20):e152740.
   PubMed Web of Science ®Google Scholar
• Bajpai M, Maheshwari A, Dogra V, et al. Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). BMJ Open. 2022;12(4):e055189.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–393.
   PubMed Web of Science ®Google Scholar
• Pang J, Xu F, Aondio G, et al. Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat Commun. 2021;12(1):814.
   PubMed Web of Science ®Google Scholar
• Self WH, Sandkovsky U, Reilly CS, et al. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2022;22:622–635.
   PubMed Web of Science ®Google Scholar
• ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022; S2213-2600(22):00215–6.
   Google Scholar
• Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385(15):1382–1392.
   PubMed Web of Science ®Google Scholar
• Bonaventura A, Vecchié A, Wang TS, et al. Targeting GM-CSF in COVID-19 pneumonia: rationale and strategies. Front Immunol. 2020;11:1625.
   PubMed Web of Science ®Google Scholar
• Mehta P, Porter JC, Manson JJ, et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respir Med. 2020;8(8):822–830.
   PubMed Web of Science ®Google Scholar
• Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2021;10(3):237–246. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Albertus Beishuizen J, Bocca Ruiz X, Boughanmi H, et al. A randomized trial of otilimab in severe COVID-19 pneumonia (OSCAR). medRxiv. 2021.
   Google Scholar
• Wilfong EM, Matthay MA. Intravenous immunoglobulin therapy for COVID-19 ARDS. Lancet Respir Med. 2021;10(2):123–125. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Nguyen AA, Habiballah SB, Platt CD, et al. Immunoglobulins in the treatment of COVID-19 infection: proceed with caution! Clin Immunol. 2020;216:108459.
   PubMed Web of Science ®Google Scholar
• Polizzotto MN, Nordwall J, Babiker AG, et al. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. Lancet. 2022;399(10324):530–540.
   PubMed Web of Science ®Google Scholar
• Mazeraud A, Jamme M, Mancusi RL, et al. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;10(2):158–166.
   PubMed Web of Science ®Google Scholar
• Xiang H, Cheng X, Li Y, et al. Efficacy of IVIG (intravenous immunoglobulin) for Corona virus disease 2019 (COVID-19): a meta-analysis. Int Immunopharmacol. 2021;96:107732.
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19). JAMA. 2020;323(18):1824–1836.
   PubMed Web of Science ®Google Scholar
• Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CL pro) structure: basis for design of anti-SARS drugs. Science. 2003;300(5626):1763–1767.
   PubMed Web of Science ®Google Scholar
• Horby PW, Mafham M, Bell JL, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–1352.
   PubMed Web of Science ®Google Scholar
• Kalantari S, Fard SR, Maleki D, et al. Comparing the effectiveness of atazanavir/ritonavir/dolutegravir/hydroxychloroquine and lopinavir/ritonavir/hydroxychloroquine treatment regimens in COVID-19 patients. J Med Virol. 2021;93(12):6557–6565.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Gordon AC, Derde LPG, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine. 2021;47(8):867–886.
   PubMed Web of Science ®Google Scholar
• Nojomi M, Yassin Z, Keyvani H, et al. Effect of arbidol (umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis. 2020;20(1):954.
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408.
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, da Silva Mm G, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520.
   PubMed Web of Science ®Google Scholar
• RECOVERY. Molnupiravir to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19 [Internet]. RECOVERY. 2022 20 July 2022. Available from: https://www.recoverytrial.net/news/molnupiravir-to-be-investigated-by-the-recovery-trial-as-a-potential-treatment-for-patients-hospitalised-with-covid-19?1af47628-0cca-11ed-8e22-0a442fc5b724.
   Google Scholar
• Jermain B, Hanafin PO, Cao Y, et al. Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing. J Pharm Sci. 2020;109(12):3574–3578.
   PubMed Web of Science ®Google Scholar
• Peña‐Silva R, Duffull SB, Steer AC, et al. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19. Br J Clin Pharmacol. 2021;87(3):1589–1590.
   PubMed Web of Science ®Google Scholar
• Mohan A, Tiwari P, Suri TM, et al. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial. J Infect Chemother. 2021;27(12):1743–1749.
   PubMed Web of Science ®Google Scholar
• Lim S, Hor C, Tay K, et al. Additional information about source of study drug and typographical error in supplement. JAMA Intern Med. 2022;182:690.
   Google Scholar
• Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of coronavirus disease 2019: a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2022;74(6):1022–1029.
   PubMed Web of Science ®Google Scholar
• Babalola OE, Bode CO, Ajayi AA, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. QJM An Int J Med. 2022;114(11):780–788.
   PubMed Web of Science ®Google Scholar
• Dyer O. Covid-19: Mexico City gave ivermectin kits to people with covid in “unethical” experiment. BMJ. 2022;376:o453.
   PubMedGoogle Scholar
• Meyerowitz-Katz G, Wieten S, Medina Arellano MDJ, et al. Unethical studies of ivermectin for covid-19. BMJ. 2022;377:o917.
   PubMedGoogle Scholar
• Blum VF, Cimerman S, Hunter JR, et al. Nitazoxanide superiority to placebo to treat moderate COVID-19 – a Pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine. 2021;37:100981.
   PubMedGoogle Scholar
• Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021;58(1):2003725.
   PubMed Web of Science ®Google Scholar
• Smith T, Hoyo-Vadillo C, Adom AA, et al. Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE). Trials. 2022;23(1):583.
   PubMedGoogle Scholar
• Rocco PRM, Silva PL, Cruz FF, et al. Nitazoxanide in patients hospitalized with COVID-19 pneumonia: a multicentre, randomized, double-blind, placebo-controlled trial. Front Med. 2022;9:844728.
   PubMed Web of Science ®Google Scholar
• Jorge A. Hydroxychloroquine in the prevention of COVID-19 mortality. Lancet Rheumatol. 2021;3(1):e2–e3.
   PubMedGoogle Scholar
• Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12(1):2349.
   PubMed Web of Science ®Google Scholar
• Fantini J, Chahinian H, Yahi N. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. Int J Antimicrob Agents. 2020;56(2):106020.
   Web of Science ®Google Scholar
• Abd-Elsalam S, Esmail ES, Khalaf M, et al. Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. Am J Trop Med Hyg. 2020;103(4):1635–1639.
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
   PubMed Web of Science ®Google Scholar
• Ulrich RJ, Troxel AB, Carmody E, et al. Treating COVID-19 With Hydroxychloroquine (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients. Open Forum Infect Dis. 2020;7(10):ofaa446.
   PubMed Web of Science ®Google Scholar
• The RECOVERY collaborative group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030–2040.
   PubMed Web of Science ®Google Scholar
• Sarhan RM, Harb HS, Abou Warda AE, et al. Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients. J Infect Public Health. 2022;15(1):116–122.
   PubMed Web of Science ®Google Scholar
• Sivapalan P, Ulrik CS, Lapperre TS, et al. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. Eur Respir J. 2022;59(1):2100752.
   PubMed Web of Science ®Google Scholar
• Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19. JAMA. 2020;324(21):2165.
   PubMed Web of Science ®Google Scholar
• RECOVERY collaborative group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605–612.
   PubMed Web of Science ®Google Scholar
• Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19. Ann Intern Med. 2020;173(8):623–631.
   PubMed Web of Science ®Google Scholar
• Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomized, controlled trial. Clin Infect Dis. 2021;73(11):e4073–e4081.
   PubMed Web of Science ®Google Scholar
• Omrani AS, Pathan SA, Thomas SA, et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine. 2020;29-30:100645.
   Google Scholar
• Butler CC, Dorward J, L-M Y, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397(10279):1063–1074.
   PubMed Web of Science ®Google Scholar
• Hinks TSC, Cureton L, Knight R, et al. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. Lancet Respir Med. 2021;9(10):1130–1140.
   PubMed Web of Science ®Google Scholar
• Chi G, Memar Montazerin S, Lee JJ, et al. Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID‐19: network meta‐analysis of randomized controlled trials. J Med Virol. 2021;93(12):6737–6749.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Mehta AK, Patterson TF, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(12):1365–1376.
   PubMed Web of Science ®Google Scholar
• Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704.
   PubMed Web of Science ®Google Scholar
• Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, et al. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep. 2021;11(1):8059.
   PubMed Web of Science ®Google Scholar
• Robba C, Battaglini D, Ball L, et al. Coagulative disorders in critically Ill COVID-19 patients with acute distress respiratory syndrome: a critical review. J Clin Med. 2021;10(1):140.
   Web of Science ®Google Scholar
• Lemos ACB, Do Espírito Santo DA, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res. 2020;196:359–366.
   PubMed Web of Science ®Google Scholar
• Mazloomzadeh S, Khaleghparast S, Ghadrdoost B, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit. JAMA. 2021;325(16):1620.
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Talasaz AH, Rashidi F, et al. Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation In Patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION randomized trial. Thromb Haemost. 2022;122(1):131–141.
   PubMedGoogle Scholar
• Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253–2263.
   PubMed Web of Science ®Google Scholar
• The ATTACC, ACTIV-4a and R-CI. Therapeutic Anticoagulation with heparin in noncritically Ill patients with Covid-19. N Engl J Med. 2021;385(9):790–802.
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19. JAMA Intern Med. 2021;181(12):1612.
   PubMed Web of Science ®Google Scholar
• Parisi R, Costanzo S, Di Castelnuovo A, et al. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost. 2021;47(4):372–391.
   PubMedGoogle Scholar
• Yasuda H, Mayumi T, Okano H. Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. Infection. 2022. 10.1007/s15010-022-01809-8
   PubMed Web of Science ®Google Scholar
• Kow CS, Ramachandram DS, Hasan SS. The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. J Infect Chemother. 2022;28(2):257–265.
   PubMed Web of Science ®Google Scholar
• Iglesias J, Vassallo AV, Patel VV, et al. Outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of sepsis. Chest. 2020;158(1):164–173.
   PubMed Web of Science ®Google Scholar
• Kashiouris MG, L’Heureux M, Cable CA, et al. The emerging role of vitamin C as a treatment for sepsis. Nutrients. 2020;12(2):292.
   PubMed Web of Science ®Google Scholar
• Majidi N, Rabbani F, Gholami S, et al. The Effect of vitamin c on pathological parameters and survival duration of critically Ill coronavirus disease 2019 patients: a randomized clinical trial. Front Immunol. 2021;12:717816.
   PubMed Web of Science ®Google Scholar
• JamaliMoghadamSiahkali S, Zarezade B, Koolaji S, et al. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. Eur J Med Res. 2021;26(1):20.
   PubMed Web of Science ®Google Scholar
• Fisher SA, Rahimzadeh M, Brierley C, et al. The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: a systematic review PLoS One. 2019;14(9):e0222313.
   Web of Science ®Google Scholar
• Ul Afshan F, Nissar B, Chowdri NA, et al. Relevance of vitamin D3 in COVID-19 infection. Gene Rep. 2021;24:101270.
   PubMed Web of Science ®Google Scholar
• De Niet S, Trémège M, Coffiner M, et al. Positive effects of vitamin d supplementation in patients hospitalized for COVID-19: a randomized, double-blind, placebo-controlled trial. Nutrients. 2022;14(15):3048.
   PubMed Web of Science ®Google Scholar
• Annweiler C, Beaudenon M, Gautier J, et al. High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trialPLOS Med. 2022;19(5):e1003999.
   Google Scholar
• Mariani J, Antonietti L, Tajer C, et al. . In: High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: multicentre randomized controlled clinical trialPLoS One. 2022;17(5):e0267918.
   Google Scholar
• Cannata-Andía JB, Díaz-Sottolano A, Fernández P, et al. A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial. BMC Med. 2022;20(1):83.
   PubMed Web of Science ®Google Scholar
• Khoury M, Cuenca J, Cruz FF, et al. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020;55(6):2000858.
   PubMed Web of Science ®Google Scholar
• Qu W, Wang Z, Hare JM, et al. Cell-based therapy to reduce mortality from COVID-19: systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020;9(9):1007–1022.
   PubMed Web of Science ®Google Scholar
• Weiss DJ, Filiano A, Galipeau J, et al. An ISCT MSC committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for COVID-19: time for a global registry. Cytotherapy. 2022. 10.1016/j.jcyt.2022.07.010.
   Google Scholar
• Kirkham AM, Monaghan M, Bailey AJM, et al. Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol. Syst Rev. 2021;10(1):249.
   PubMed Web of Science ®Google Scholar
• Kirkham AM, Bailey AJM, Monaghan M, et al. Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a framework for accelerated synthesis of trial evidence for rapid approval—FASTER approval. Stem Cells Transl Med. 2022;11(7):675–687.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs. New J Chem. 2021;45(2):761–771.
   Web of Science ®Google Scholar
• Kong R et al. COVID-19 Docking Server: a meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19. Bionformtics 20 July 2022: ;36(20):5109–5111
   Google Scholar
• Rabie AM. CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy. Mol Divers. 2021;25(3):1839–1854.
   PubMed Web of Science ®Google Scholar
• Rabie AM. New potential inhibitors of coronaviral main protease (CoV-Mpro): strychnine bush, pineapple, and ginger could be natural enemies of COVID-19. Int J new Chem. 2022;9:433–445.
   Google Scholar
• Rabie AM. Discovery of Taroxaz-104: the first potent antidote of SARS-CoV-2 VOC-202012/01 strain. J Mol Struct. 2021;1246:131106.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles. Chem Biol Interact. 2021;343:109480.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Cyanorona-20: the first potent anti-SARS-CoV-2 agent. Int Immunopharmacol. 2021;98:107831.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Efficacious preclinical repurposing of the nucleoside analogue didanosine against COVID-19 polymerase and exonuclease. ACS Omega. 2022;7(25):21385–21396.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication. ACS Omega. 2022;7(3):2960–2969.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Teriflunomide: a possible effective drug for the comprehensive treatment of COVID-19. Curr Res Pharmacol Drug Discov. 2021;2:100055.
   PubMedGoogle Scholar
• Janiaud P, Hemkens LG, Ioannidis JPA. Challenges and lessons learned from COVID-19 trials: should we be doing clinical trials differently? Can J Cardiol. 2021;37(9):1353–1364.
   PubMed Web of Science ®Google Scholar
• Salonius K, Simard N, Harland R, et al. The road to licensure of a DNA vaccine. Curr Opin Invest Drugs. 2007;8(8):635–641.
   PubMedGoogle Scholar
• Akhondzadeh S, Shamabadi A. Medical biotechnology in the service of coronavirus vaccine discovery and production. Avicenna J Med Biotechnol. 2021;13(3):105–106.
   PubMedGoogle Scholar
• Baxter. Regulatory approval in the Covid era: how the pandemic changed drug development [Internet]. Pharm. Technol. 2022 20 July 2022. Available from: https://www.pharmaceutical-technology.com/sponsored/regulatory-approval-in-the-covid-era-how-the-pandemic-changed-drug-development/.
   Google Scholar
• Klein K, Stolk P, Tellner P, et al. Regulatory flexibilities and guidances for addressing the challenges of COVID-19 in the EU: what can we learn from company experiences? Ther Innov Regul Sci. 2022;56(2):366–377.
   PubMed Web of Science ®Google Scholar
• Park JJH, Mogg R, Smith GE, et al. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob Heal. 2021;9(5):e711–e720.
   PubMed Web of Science ®Google Scholar
• Webb SA, Higgins AM, McArthur CJ. Glucocorticoid Dose in COVID-19. JAMA. 2021;326(18):1801.
   PubMed Web of Science ®Google Scholar
• Itaya T, Isobe Y, Suzuki S, et al. The fragility of statistically significant results in randomized clinical trials for COVID-19. JAMA Network Open. 2022;5(3):e222973.
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Epstein M, Zannad F. the decline of the experimental paradigm during the COVID-19 pandemic: a template for the future. Am J Med. 2021;134(2):166–175.
   PubMed Web of Science ®Google Scholar
• Kimmel SE, Califf RM, Dean NE, et al. COVID-19 clinical trials: a teachable moment for improving our research infrastructure and relevance. Ann Intern Med. 2020;173(8):652–653.
   PubMed Web of Science ®Google Scholar
• Li H, Yan B, Gao R, et al. Effectiveness of corticosteroids to treat severe COVID-19: a systematic review and meta-analysis of prospective studies. Int Immunopharmacol. 2021;100:108121.
   PubMed Web of Science ®Google Scholar
• Viswanatha GL, Male CKVLSN A, Shylaja H. Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies. Pathog Rheum arthritis one year Rev. 2022;40:634–646.
   Google Scholar
• Horbach SPJM. Pandemic publishing: medical journals strongly speed up their publication process for COVID-19. Quant Sci Stud. 2020;1(3):1056–1067
   Google Scholar
• Robba C, Battaglini D, Ball L, et al. Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. Respir Physiol Neurobiol. 2020;279:103455.
   PubMed Web of Science ®Google Scholar
• Tonelli R, Marchioni A, Tabbì L, et al. Spontaneous breathing and evolving phenotypes of lung damage in patients with COVID-19: review of current evidence and forecast of a new scenario. J Clin Med. 2021;10(5):975.
   PubMed Web of Science ®Google Scholar
• Laffey JG, Kavanagh BP. F ifty Y ears of R esearch in ARDS.Insight into acute respiratory distress syndrome. From models to patients. Am J Respir Crit Care Med. 2017;196(1):18–28. .
   PubMed Web of Science ®Google Scholar
• Wilson JG, Calfee CS. ARDS subphenotypes: understanding a heterogeneous syndrome. Crit Care. 2020;24(1):102.
   PubMed Web of Science ®Google Scholar
• Millar JE, Wildi K, Bartnikowski N, et al. Characterizing preclinical sub‐phenotypic models of acute respiratory distress syndrome: an experimental ovine study. Physiol Rep. 2021;9(19):e15048.
   PubMed Web of Science ®Google Scholar
• Zhai R, Bonda WLM, Matute-Bello G, et al. From preclinical to clinical models of acute respiratory distress syndrome. Signa Vitae. 2021;18: 3–14.
   Web of Science ®Google Scholar
• Samanta RJ, Summers C. Translational research in intensive care unit: novel approaches for drug development and personalized medicine. Semin Respir Crit Care Med. 2019;40(5):687–698.
   PubMed Web of Science ®Google Scholar
• Battaglini D, Robba C, Pelosi P, et al., Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials. Expert Opin Emerg Drugs. 2022;27(2): 187–209.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Ruschitzka F, Patel AN. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Desai SS, Kuy S, et al. Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382(26):2582.
   PubMed Web of Science ®Google Scholar
• Sinha P, Delucchi KL, McAuley DF, et al. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020;8(3):247–257.
   PubMed Web of Science ®Google Scholar
• Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377–1380. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• FDA. Coronavirus (COVID-19) update: FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against omicron variant [Internet]. Press Annunc. 2022 cited 2022 Mar 24]. Available from 2022 Mar 24: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains.
   Google Scholar
• Westendorf K, Wang L, Žentelis S, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxiv. 2022; Preprint. 10.1101/2021.04.30.442182.
   PubMedGoogle Scholar